Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Large Cell Carcinoma Lung Clear all
Terminated Phase 2 Interventional Results available

Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

NCT00528775
View directory record Official record
Conditions
Lung Cancer
Interventions
HPPH, endoscopic procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2 Interventional

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00309998
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, vinorelbine tartrate
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 1 Interventional

SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

NCT02500914
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
SC-002
Drug
Lead sponsor
Stemcentrx
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 10, 2026, 8:07 AM EDT
Active, not recruiting Not applicable Interventional

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT01345851
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 3 Interventional

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

NCT00028938
View directory record Official record
Conditions
Lung Cancer
Interventions
epoetin alfa, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2 Interventional

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00003089
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jun 10, 2026, 8:07 AM EDT
Active, not recruiting Phase 1 Interventional

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

NCT05680922
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
LB2102
Biological
Lead sponsor
Legend Biotech USA Inc
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Tampa, Florida • Lexington, Kentucky • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 1 Interventional

Safety Study of SEA-CD40 in Cancer Patients

NCT02376699
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Interventions
Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2 Interventional

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00003269
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2Phase 3 Interventional

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

NCT00021060
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jun 10, 2026, 8:07 AM EDT
Completed No phase listed Observational

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

NCT03351140
View directory record Official record
Conditions
Neoplasms
Interventions
Qualitative Interviews, PROMIS Physical Function Items
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791
View directory record Official record
Conditions
Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma
Interventions
PDR001, LAG525
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jun 10, 2026, 8:07 AM EDT
Active, not recruiting Phase 1 Interventional

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

NCT06736418
View directory record Official record
Conditions
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
225Ac-ABD147
Drug
Lead sponsor
Abdera Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Newport Beach, California • San Francisco, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 3 Interventional Results available

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

NCT02737501
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions
Brigatinib, Crizotinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Sedona, Arizona • Bellflower, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 1 Interventional

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

NCT04432207
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
Interventions
IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3, Atezolizumab, Standard of care chemotherapy
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00368992
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cetuximab, paclitaxel, bevacizumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2015 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 10, 2026, 8:07 AM EDT
Completed Phase 2 Interventional

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

NCT00006019
View directory record Official record
Conditions
Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Prostate Cancer
Interventions
azacitidine, sodium phenylbutyrate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

NCT00596830
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 2 Interventional Results available

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04644315
View directory record Official record
Conditions
Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Culver City, California • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jun 10, 2026, 8:07 AM EDT
Terminated Phase 2 Interventional Results available

Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00526890
View directory record Official record
Conditions
Lung Cancer
Interventions
selenomethionine, carboplatin, paclitaxel, laboratory biomarker analysis, radiation therapy
Dietary Supplement · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Jun 10, 2026, 8:07 AM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

NCT03110978
View directory record Official record
Conditions
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Lung Non-Small Cell Squamous Carcinoma, Minimally Invasive Lung Adenocarcinoma, Neuroendocrine Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Large Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8
Interventions
Nivolumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Conroe, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 10, 2026, 8:07 AM EDT